Arbidol antiviral agent Uminofenovir 100 mg 20 capsules

Arbidol antiviral agent Uminofenovir 100 mg 20 capsules

Expiration date: 01.2024

• Free shipping
• Detailed instructions in English are attached
• Over-the-counter drug
ARBIDOL® acts on various pathogens of acute respiratory viral infections, showing activity against influenza viruses of types A and B, rhinovirus, korona virus, respiratory syncytial virus, rotovirus, as well as a number of other viruses – causative agents of respiratory infections.
ARBIDOL® blocks the early stage of reproduction (reproduction) of viruses, prevents the fusion of viruses with the membrane (membrane) of the endosome, stops the spread of viruses in the body.

RELEASE FORM:
100 mg capsules: 20 pcs.
Active substance: Umifenovir
Release form, composition and packaging
Hard gelatin capsules, size No. 1, white case, yellow cap; capsule contents – a mixture containing granules and powder from white to white with a greenish yellowish or creamy hue.
1 caps .
Umifenovir hydrochloride (in the form of Umifenovir hydrochloride monohydrate) 100 mg
Excipients: potato starch - 30.14 mg, microcrystalline cellulose - 55.76 mg, colloidal silicon dioxide ( aerosil ) - 2 mg, povidone K25 ( collidone 25) - 10.1 mg, calcium stearate - 2 mg.
The composition of the capsule body: titanium dioxide (E171) - 2%, gelatin - up to 100%. The composition of the capsule cap: titanium dioxide (E171) - 1.3333%, dye sun sunset yellow (E110) 0.0044%, quinoline yellow (E104) - 0.9197%, gelatin - up to 100%.

PHARMACHOLOGIC EFFECT
Antiviral drug. Specifically inhibits the in vitro viruses are influenza A and B (Influenza virus A, B), including highly subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses - activators SARS (Korona virus (Korona virus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect, increases the body's resistance to viral infections. It has interferon-inducing activity – in a study on mice, the induction of interferons was observed after 16 hours, and high titers of interferons remained in the blood until 48 hours after administration. Stimulates cellular and humoral immunity reactions: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T- suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells).
Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the frequency of development of complications associated with a viral infection and exacerbations of chronic bacterial diseases.
Refers to low-toxic drugs (LD 50 > 4 g / kg). It does not have any negative effects on the human body when administered orally in recommended doses.

PHARMACOKINETICS
Suction and distribution
Quickly absorbed from the digestive tract. C max in plasma is reached after 1.5 hours.
Umifenovir is rapidly distributed to organs and tissues of the body.

METABOLISM AND EXCRETION
Metabolized in the liver. T 1/2 is 17-21 hours.
About 40% is excreted unchanged, mainly with bile (38.9%) and in insignificant amounts by the kidneys (0.12%). During the first day, 90% of the dose taken is excreted.

INDICATIONS
• prevention and treatment in adults and children: influenza A and B, other acute respiratory viral infections;
• complex therapy of acute intestinal infections of rotavirus etiology in children over 6 years old;
• complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection;
• prevention of postoperative infectious complications.

DOSAGE REGIMEN
The drug is taken orally, before meals.
Single dose: for children aged 6 to 12 years - 100 mg (1 capsule), for adults and children over 12 years of age - 200 mg (2 capsules of 100 mg)
For non-specific prevention and treatment of influenza and other acute respiratory viral infections in children and adults

NONSPECIFIC PREVENTION
During the period of the epidemic of influenza and other acute respiratory viral infections: children from 6 to 12 years old - 100 mg, children over 12 years old and adults - 200 mg 2 times a week for 3 weeks.
In direct contact with patients with influenza and other acute respiratory viral infections - children 6 to 12 years old - 100 mg, children over 12 years old and adults - 200 mg 1 time / day for 10-14 days.

TREATMENT OF INFLUENZA AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS
Children from 6 to 12 years old - 100 mg, children over 12 years old and adults - 200 mg 4 times / day (every 6 hours) for 5 days.
Complex therapy of acute intestinal infections of rotavirus etiology in children over 6 years old
Children from 6 to 12 years old - 100 mg, children over 12 years old - 200 mg 4 times / day (every 6 hours) for 5 days.
In the complex treatment of chronic bronchitis, pneumonia and recurrent herpetic infection
Children from 6 to 12 years old - 100 mg, children over 12 years old and adults - 200 mg 4 times / day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.

PREVENTION OF POSTOPERATIVE COMPLICATIONS
Children from 6 to 12 years old - 100 mg, children over 12 years old and adults - 200 mg 2 days before surgery, then on 2 and 5 days after surgery.

SIDE EFFECT
Rarely: allergic reactions.
If these side effects are exacerbated, or any other side effects appear, the patient should inform the doctor.

CONTRAINDICATIONS
• hypersensitivity to umifenovir or any component of the drug;
• children under 6 years old;
• I trimester of pregnancy.

PREGNANCY AND LACTATION
Animal studies have not revealed harmful effects on pregnancy, the development of the embryo and fetus, labor and postnatal development.
The use of the drug Arbidol ® in the first trimester of pregnancy is contraindicated.
In the second and third trimesters of pregnancy, Arbidol ® can only be used for the treatment and prevention of influenza, and if the intended benefit to the mother outweighs the potential risk to the fetus. The benefit / risk ratio is determined by the attending physician.
It is not known whether Arbidol ® is excreted in breast milk in women during lactation. If necessary, the use of the drug Arbidol ® should stop breastfeeding.

USE IN CHILDREN
The use of the drug in children under 6 years is contraindicated.
special instructions
It is necessary to observe the recommended scheme and the duration of the drug. If you miss one dose of the drug, you should take the missed dose as soon as possible and continue the course of taking the drug according to the scheme begun.
Impact on the ability to drive vehicles and mechanisms
It does not show central neurotropic activity and can be used in medical practice in people of various professions requiring increased attention and speed of psychomotor reactions (including transport drivers, operators).

OVERDOSE
Cases of drug overdose are not marked.

DRUG INTERACTION
When prescribed with other drugs, no negative effects were noted.
Terms and conditions of storage
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C. Shelf life is 3 years. Do not use after the expiration date indicated on the package.

PHARMACY VACATION TERMS
The drug is dispensed without a prescription.